Robert Kamen

Dr. Robert I.
Kamen is a Senior Advisor at Shangbay Capital Management Co. LLC, an Independent Non-Executive Director at Harbour BioMed (Shanghai) Co., Ltd., an Independent Non-Executive Director at HBM Holdings Ltd., an Advisory Partner at Third Rock Ventures LLC and a Member at European Molecular Biology Organization.
He is on the Board of Directors at Harbour BioMed (Shanghai) Co., Ltd., HBM Holdings Ltd., EpimAb Biotherapeutics, Inc., Lycera Corp.
and Shanghai EpimAb Biotherapeutics Co. Ltd. Dr. Kamen was previously employed as an Independent Director by Neon Therapeutics, Inc., an Independent Director by Jounce Therapeutics, Inc., a Board of Directors by Anchor Therapeutics, Inc., a Board Of Directors by Velocon Sports Inc, a Chairman by BioAssets Development Corp., a President by Abbot Bioresearch Center, Inc., a President by Abbott Bioresearch Center, a President by BASF Bioresearch Corp., and a Senior Vice President-Scientific Affairs by Genetics Institute, Inc. He also served on the board at Opsonic Therapeutics, Inc. and Harbour Antibodies BV.
He received his undergraduate degree from Amherst College and a doctorate degree from Harvard University.